/
CYTK
$85.39-$1.88 (-2.15%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$11.2B
136M shares
52-week range
$32.66 – $88.31
95% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
0.40%
Easy to borrow
Price (6 mo)
Loading chart…
Change+$64.41
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $31.5M | $26.9M | $55.8M | $70.4M | $94.6M | $7.5M | $18.5M | $88.0M |
| Cost of revenue | $89.1M | $86.1M | $97.0M | $159.9M | $240.8M | $330.1M | $339.4M | $10.1M |
| Gross profit | −$57.6M | −$59.3M | −$41.1M | −$89.5M | −$146.2M | −$322.6M | −$320.9M | $77.9M |
| Gross margin | -183.0% | -220.5% | -73.7% | -127.1% | -154.6% | -4284.1% | -1737.2% | 88.5% |
| R&D | $89.1M | $86.1M | $97.0M | $159.9M | $240.8M | $330.1M | $339.4M | $405.9M |
| Operating income | −$88.9M | −$98.9M | −$93.9M | −$186.3M | −$324.2M | −$496.2M | −$536.2M | −$612.3M |
| EBITDA | −$83.5M | −$93.0M | −$86.8M | −$176.3M | −$329.4M | −$456.7M | −$493.5M | −$775.3M |
| Net income | −$106.3M | −$121.7M | −$127.3M | −$215.3M | −$389.0M | −$526.2M | −$589.5M | −$785.0M |
| Net margin | -337.4% | -452.9% | -228.0% | -305.7% | -411.2% | -6988.6% | -3191.1% | -891.6% |
| EPS (diluted) | -1.95 | -2.59 | -1.97 | -2.80 | -4.33 | -5.45 | -5.26 | -6.54 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $109M | $-6.39 | $-7.41–$-4.17 | 15 |
| 2027 | $392M | $-4.65 | $-5.57–$-2.93 | 14 |
| 2028 | $885M | $-1.81 | $-3.73–$0.10 | 14 |
| 2029 | $1.5B | $0.84 | $0.63–$1.28 | 8 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
Cytokinetics Inc.
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
www.cytokinetics.com- Employees
- 673
- IPO / List date
- Apr 29, 2004
- HQ
- SOUTH SAN FRANCISCO, CA
Held by traders on TradeandTell
No one on the platform currently holds CYTK.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2025-12-31 | 172,067 | $10.9M |
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2013-06-25 | 1-for-6reverse |
Recent trades on TradeandTell
No one on the platform has traded CYTK yet.
